Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical 0.05% oxymetazoline for post-acne erythema (split-face, randomized, double-blind)
TCTR20211207004Phase 4Completed
- Sponsor
- N/A
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oxymetazoline in Postinflammatory erythema (PIE), sponsored by N/A. Started Dec 2021; status: completed.
02
Drugs
oxymetazoline
03
Conditions
Postinflammatory erythema (PIE)
Beyond the preview
Go deeper on TCTR20211207004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211207004.